

# Greg Fenton on how ZEN Graphene's disease detection technology will "revolutionize the way testing is done"

written by InvestorNews | June 18, 2021

In a recent InvestorIntel interview, Tracy Weslosky speaks with Greg Fenton, CEO and Director of [ZEN Graphene Solutions Ltd.](#) (TSXV: ZEN) about ZEN's [exclusive worldwide rights](#) to commercialize rapid, saliva-based COVID-19 antigen testing technology announced yesterday

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Greg went on to say that this saliva-based test is exceptionally accurate, similar to current PCR tests, and will "revolutionize the way testing is done". Affordable, easy to use, scalable and provides results in under 10 minutes, Greg comments that this technology has the ability "to allow economies to reopen." Tracy then asks the critical question with "will you be able to test for anything?"

To find out – watch the full interview, [click here](#)

## About ZEN Graphene Solutions Ltd.

ZEN is a next-gen nanomaterials technology company developing and commercializing technologies that help protect people and the environment. ZEN is currently focused on commercializing **ZEN Guard**™, a patent pending graphene-based coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar graphene compounds as

pharmaceutical products against infectious diseases. The company has a significant R&D pipeline with an interest in monomers, polymers, metal alloys, corrosion coatings, biosensors along with the production of graphene oxide and graphene quantum dots. Additionally, the company owns the unique Albany Graphite Project which provides the company with a potential competitive advantage in the graphene market. Labs in Japan, UK, Israel, USA, and Canada have independently demonstrated that ZEN's Albany Pure™ Graphite is an ideal precursor material that easily converts (exfoliates) to graphene, using a variety of mechanical, chemical, and electrochemical methods.

To learn more about ZEN Graphene Solutions Ltd., [click here](#)

**Disclaimer:** ZEN Graphene Solutions Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on [www.Sedar.com](http://www.Sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email [info@investorintel.com](mailto:info@investorintel.com).

---

## **StageZero Saliva PCR Test, a potential game changer for replacing the nasal probe**

written by InvestorNews | June 18, 2021

Nobody likes a COVID-19 nasal swab test that pushes a probe way up into your nose nearly reaching your brain. [StageZero Life Sciences Ltd.](#) (TSX: SZLS) ('StageZero') has released a COVID-19 saliva PCR test in the USA which is so much more easier and more comfortable to do. It can even be mailed to you and done at your home.

In [news](#) just released yesterday, StageZero released their new COVID-19 Saliva PCR test in the USA and Canada. Since May 2020, StageZero has been offering nasopharyngeal swab-based PCR tests

and serology tests for COVID-19. The good news is that StageZero has now added a saliva test and will shortly introduce an antigen test and a full viral respiratory panel to its test offering. The test is FDA approved under the Emergency Use Authorization (EUA) clearance. All the patient has to do is simply fill a tube with their own saliva, label it, and send it to the StageZero lab for testing.

## **COVID-19 PCR test – Uncomfortable nasal swab versus simple saliva testing**



### [Source](#)

Chairman and CEO of StageZero, James Howard-Tripp, [says](#): “Every COVID testing lab, and Government, is striving to make testing more accessible and easier to do. Saliva as a specimen, done correctly, is scientifically as accurate as swabs but easier to collect and allows us to reach patients at home.”

Back in May when StageZero first introduced the nasal swab tests I [wrote](#) about the massive worldwide demand for COVID-19 testing. I quoted a [report](#) by Harvard University stating that the US needs to be able to test 5 million people per day to safely begin to reopen their economy by June 2020. That was when there were only 30,000 new cases per day in the USA.

Fast forward to today and there are now about [45,000](#) new COVID-19 cases per day in the US, and about 1 million new COVID-19 tests performed every day. But really the need for testing remains much higher.

## **US daily COVID-19 tests tracker by John Hopkins – About 1 million tests per day**



## [Source](#)

StageZero will continue to offer a selection of COVID-19 testing summarized as:

- Salvia PCR tests to detect the SARS-CoV-2 RNA and then sent to the StageZero Virginia lab for results processing. Ideal for very early stage detection.
- Antigen testing for immediate results. This works by testing if a patient has developed antibodies to COVID-19. It is best for the rapid screening of symptomatic patients.
- A Respiratory Panel PCR-based test for 18 viruses and two respiratory bacteria. It will screen for Influenza A, Influenza B, RSV and SARS-CoV-2 infection.

StageZero now offers a complete range of COVID-19 tests at a time when demand for testing is enormous. My view is that patient's will be much more willing to undergo a saliva test than the previous nasal swab testing, as well as the possibility of completing a test from home. It is also much more suitable for people in remote areas.

Looking ahead in the very near term, StageZero will commence an offering with their revolutionary [Aristotle®](#) screening test for 10 cancers from a single sample of blood. You can read more about that [here](#).

Following the recent [share consolidation](#) StageZero will now "prepare for a possible future [listing on NASDAQ or other senior US stock exchange](#)". Both of these events should be strong catalysts to help the stock price potentially move higher.

StageZero Life Sciences trades with a market cap of just C\$41 million. Analyst's consensus price target is [C\\$4.00](#), so there is still plenty of potential upside ahead given the current stock

price of C\$0.84.

**Disclaimer:** Matt Bohlsen is a shareholder of StageZero Life Sciences Ltd. (TSX: SZLS)